Protease

Overview

A protease is an enzyme that cleaves peptide bonds. Proteases are the molecular scissors of biology: they digest dietary protein, activate zymogens, degrade misfolded or damaged proteins, execute cell death, and regulate signaling by activating or inactivating effectors through targeted cleavage.

Every peptide therapeutic must survive a gauntlet of endogenous proteases between administration and its target receptor. For this reason, protease stability is a dominant consideration in peptide drug design.

Detailed Explanation

Proteases catalyze hydrolysis of the C–N peptide bond:

R–C(=O)–N(H)–R' + H₂O → R–C(=O)–OH + H₂N–R'

Classical classification is based on the catalytic residue or mechanism:

• Serine proteases — trypsin, chymotrypsin, elastase, thrombin, plasmin. Use a Ser/His/Asp catalytic triad.
• Cysteine proteases — caspases, cathepsins B/L/S, calpains. Use an active-site cysteine.
• Aspartyl proteases — pepsin, renin, HIV protease, β-secretase. Use two aspartate residues.
• Metalloproteases — matrix metalloproteinases (MMPs), ACE, neprilysin. Require zinc as cofactor.
• Threonine proteases — proteasome subunits.
• Glutamic and asparagine proteases — rarer, mostly microbial.

Proteases differ in specificity: trypsin cleaves after Lys/Arg, chymotrypsin after aromatic residues, elastase after small residues, while caspases require strict sequence motifs.

Where Proteases Matter

Digestion and absorption

Oral peptide therapeutics face pepsin in the stomach, followed by pancreatic trypsin, chymotrypsin, and elastase, plus brush-border enzymes in the small intestine. Most unmodified peptides do not survive this gauntlet, explaining the poor bioavailability of oral peptides.

Systemic circulation

Plasma contains aminopeptidases, dipeptidyl peptidases (DPP-4 is the famous one for GLP-1), and metalloproteinases. Subcutaneous tissue harbors additional proteases. Peptide half-life is usually determined by protease susceptibility plus renal clearance.

Intracellular

Lysosomal cathepsins, proteasomes, and caspases handle intracellular turnover and signaling.

Protease Resistance Strategies for Peptides

• D-amino acid substitution — blocks most mammalian proteases, since natural enzymes evolved to act on L-residues.
• N-methylation — shields the peptide bond's nitrogen.
• Cyclization — removes free termini for exopeptidases.
• PEGylation — sterically shields cleavage sites.
• Unnatural amino acids such as Aib to disrupt recognition motifs.
• Lipidation — albumin binding both extends half-life and masks protease sites.

Proteases as Drug Targets

• ACE inhibitors (lisinopril, enalapril) for hypertension
• HIV protease inhibitors (lopinavir, atazanavir) for AIDS
• DPP-4 inhibitors (sitagliptin) for type 2 diabetes (extends endogenous GLP-1)
• Proteasome inhibitors (bortezomib) for multiple myeloma
• Thrombin inhibitors (dabigatran, argatroban) for anticoagulation

Most follow classic competitive inhibition kinetics at the active site, though some exploit allosteric sites for selectivity.

Proteases in Cell Signaling

Proteolysis is not only degradation — it is a signaling tool. Caspases drive apoptosis, γ-secretase releases transcription factors from membrane precursors, furin and PCSK enzymes activate peptide hormones, and MMPs reshape the extracellular matrix during wound healing and tumor invasion.

Summary

Proteases are hydrolytic enzymes that govern nearly every aspect of peptide pharmacokinetics. Whether friends (activating prohormones) or foes (degrading drug candidates), they must be accounted for in any peptide development program.